ANTH Key Stats
- Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference PR Newswire Nov 27
- Anthera Pharma (ANTH) Stock Drops Street Insider Nov 19
- Two Drugs, Designed To Help Patients, Actually Hurt Them Nov 19
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Nov 15
- ANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 14
- Anthera Pharmaceuticals: Recent Developments, Both Good And Bad Oct 31
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Oct 29
- Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update noodls Oct 29
- 4 Stocks Under $10 Making Big Moves Oct 25
- A Promising Future For Anthera's Blisibimod Sep 27
ANTH Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Anthera Pharmaceuticals is down 46.27% over the last year vs S&P 500 Total Return up 30.86%, Actelion up 65.42%, and Alnylam Pharmaceuticals up 285.4%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for ANTH
Pro Strategies Featuring ANTH
Did Anthera Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.